On the contrary, serum CEA levels increased significantly in the CEA++ models after successful treatment, indicating the release of intracellular CEA resulting from the disruption of CEA++ tumor cells due to the action of CAR-T. The gene discussed is CEACAM5; the disease is neoplasm.